Appetite suppressants and valvular heart disease

Editorial

R B Devereux. N Engl J Med. 1998.

. 1998 Sep 10;339(11):765-6.

doi: 10.1056/NEJM199809103391109.

No abstract available

Comment on

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. Khan MA, et al. N Engl J Med. 1998 Sep 10;339(11):713-8. doi: 10.1056/NEJM199809103391101. N Engl J Med. 1998. PMID: 9731086
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. Jick H, et al. N Engl J Med. 1998 Sep 10;339(11):719-24. doi: 10.1056/NEJM199809103391102. N Engl J Med. 1998. PMID: 9731087
An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. Weissman NJ, et al. N Engl J Med. 1998 Sep 10;339(11):725-32. doi: 10.1056/NEJM199809103391103. N Engl J Med. 1998. PMID: 9731088 Clinical Trial.